SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: MIKE DUBIS who wrote (3027)12/4/1997 6:55:00 AM
From: RT  Read Replies (1) | Respond to of 23519
 
Mike,

VIVUS GETS NO RESPECT!
When you factor in estimated 4Q earnings Vivus will be selling at a PE of 17.
The industry's average PE is 43 !!
It's apparent investors are concerned about Vivus's ability to maintain or expand it's market once Viagara hits the market.

I personally see little downside risk at this point but I won't expect any major move past the low 30's until after Viagara is launched and Vivus proves it's still a major player.
Vivus will always be viewed with a bit of skepticism as long as it's a one product company. They are too vulnerable and need to expand their product line beyond muse.

In the meantime, will just have to wait and see.

Still a Believer,
RT



To: MIKE DUBIS who wrote (3027)12/4/1997 11:53:00 AM
From: Don Dunlap  Read Replies (1) | Respond to of 23519
 
Mike, <<What do you mean when you say "vvus is looking better than ever?" Certainly, you don't mean the stock price.>>

No, not the stock price. Fundamentally, VVUS looks better than ever. A number of hurdles have been cleared: UK approval, FDA approval of production procedures at existing factory, real earnings, a successful product release, much closer to the date of a new factory on line, continued product demand. Viagra has always been a known threat, so I don't count it as deteriorating fundamentals.

If you want some more detail of what VIVUS has overcome, read the thread "Vivus Why the Slide" around Feb 97 thru May 97. A lot of the short arguments had some validity at the time.